Amgen speaks out about bone density concerns with obesity drug

Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s comment caused a $12bn market wipe.

The company has tried to lay to rest any investor concerns after a Cantor Fitzgerald analyst raised the alarm about MariTide (maridebart cafraglutide, formerly AMG 133) on Tuesday (12 November).